Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2019030268) GLP-1/GLUCAGON RECEPTOR AGONISTS IN THE TREATMENT OF FATTY LIVER DISEASE AND STEATOHEPATITIS
Latest bibliographic data on file with the International BureauSubmit observation

Pub. No.: WO/2019/030268 International Application No.: PCT/EP2018/071478
Publication Date: 14.02.2019 International Filing Date: 08.08.2018
Chapter 2 Demand Filed: 19.02.2019
IPC:
A61K 38/22 (2006.01) ,A61K 38/26 (2006.01) ,A61P 1/16 (2006.01)
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38
Medicinal preparations containing peptides
16
Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
17
from animals; from humans
22
Hormones
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38
Medicinal preparations containing peptides
16
Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
17
from animals; from humans
22
Hormones
26
Glucagons
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
1
Drugs for disorders of the alimentary tract or the digestive system
16
for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
Applicants:
SANOFI [FR/FR]; 54 rue La Boétie 75008 Paris, FR
Inventors:
KANNT, Aimo; DE
BIELOHUBY, Maximilian; DE
ELVERT, Ralf; DE
WAGNER, Michael; DE
BOSSART, Martin; DE
HAACK, Torsten; DE
KEIL, Stephanie; DE
SEIZ, Werner; DE
Agent:
WEICKMANN & WEICKMANN PARTMBB; Postfach 860 820 81635 München, DE
Priority Data:
17 306 059.109.08.2017EP
Title (EN) GLP-1/GLUCAGON RECEPTOR AGONISTS IN THE TREATMENT OF FATTY LIVER DISEASE AND STEATOHEPATITIS
(FR) AGONISTES DU RÉCEPTEUR DE GLP-1/GLUCAGON DANS LE TRAITEMENT DE LA STÉATOSE HÉPATIQUE ET DE LA STÉATOHÉPATITE
Abstract:
(EN) The present invention relates to the medical use of specific GLP-1 /glucagon receptor agonists in the prevention and/or treatment of metabolic liver disease, particularly non-alcoholic fatty liver disease (NAFLD), more particularly non-alcoholic fatty liver (NAFL), non-alcoholic steatohepatitis (NASH) and/or NAFLD-associated liver fibrosis.
(FR) La présente invention concerne l'utilisation médicale d'agonistes spécifiques du récepteur de GLP-1/glucagon dans la prévention et/ou le traitement d'une maladie du foie métabolique, en particulier la stéatose hépatique non alcoolique (NAFLD), notamment le foie gras non alcoolique (NAFL), la stéatohépatite non alcoolique (NASH) et/ou la fibrose hépatique associée à NAFLD.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)